]]>The New Hemp Energy Drink Will Be Offered to Consumers in 700 Additional Stores in Five Provinces

OTTAWA, ON, July 18, 2019 (GLOBE NEWSWIRE) – Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that one of the largest food and convenience store chains in North America has committed to carry the Hemp Energy Drinkin over 600 stores, bringing the total number of new stores offering the product in the past two weeks to approximately 700 stores located in five provinces of Canada including: British-Columbia, Alberta, Saskatchewan, Manitoba and Ontario. Visit www.hempenergydrink.cafor store locations.

The beverages will be offered to consumers as of today in several stores with all stores in the five provinces receiving their supply within the next two weeks. The distribution commitment is for the three popular flavours of the Hemp Energy Drink – Classic, Mango and Raspberry.

“We are very pleased with this agreement because the demand for our Hemp Energy Drink has been extremely positive since the product launch,” said Tetra Natural Health CEO Richard Giguère. “This new national rollout in five provinces will allow us to better serve our ever-growing consumer base and will add to the new stores that were announced in Quebec earlier this week”.

Tetra Natural Heath is an emerging player in the identification, development and marketing of hemp or cannabinoids-based products authorized for sale by Health Canada. The new Hemp Energy Drink (HED) contains more natural ingredients than other energy drinks, and is the first energy drink made with hemp available in the Canada.

“Securing a partnership with one of the largest chains of food and convenience stores in North America validates our HED’s quality and will improve our ability to quickly meet consumer demand,” Giguère added.

About Tetra Natural Health:

Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For more information, visit: www.tetrenaturalhealth.com

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may“, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

]]>The New Hemp Energy Drink Will Soon be Available in More than 500 Stores in Quebechttps://www.tetranaturalhealth.com/2019/07/the-new-hemp-energy-drink-will-soon-be-available-in-more-than-500-stores-in-quebec/
Tue, 16 Jul 2019 12:09:12 +0000https://tetranaturalhealth.com/?p=1185The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores In Quebec OTTAWA, Ontario – July 16, 2019, (GLOBE NEWSWIRE) –Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an agreement with Distribution AB inc. for the distribution of […]

]]>The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores In Quebec

OTTAWA, Ontario – July 16, 2019, (GLOBE NEWSWIRE) –Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an agreement with Distribution AB inc. for the distribution of the three flavours of the new Hemp Energy Drink in more than 500 grocery and convenience stores located on the south shore of the St. Lawrence River, mainly in the Montéregie, Eastern Townships, Centre du Québec and Mauricie region on the north shore. The Hemp Energy Drink should be available to consumers in several stores in these regions before the end of July. Visit www.hempenergydrink.cafor store locations.

“This agreement allows us to take another step in implementing our distribution strategy. We will quickly make the three flavors of our Hemp Energy Drink available to Quebec consumers in the regions served by our partner, but we are aiming at serving all of Quebec” said Richard Giguère, CEO of Tetra Natural Health. “Consumers appreciate the qualities of the Hemp Energy Drink (HED) and its energy inducing properties. HED contains more natural ingredients than other energy drink and is the first hemp energy drink in the country”.

About Tetra Natural Health

Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information visit: www.tetranaturalhealth.com

About Tetra Bio-Pharma

Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information, visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

]]>Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Linehttps://www.tetranaturalhealth.com/2019/06/spyder-cannabis-celebrates-canada-day-weekend-with-launch-of-new-hemp-energy-drink-line/
Wed, 26 Jun 2019 13:27:19 +0000https://tetranaturalhealth.com/?p=1177Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Line Vaughan, Ontario–(Newsfile Corp. – June 26, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder Cannabis” or the “Company“) is excited to announce that, in celebration of Canada Day, it will launch its new Hemp Energy Drink line over the Canada Day […]

]]>Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Line

Vaughan, Ontario–(Newsfile Corp. – June 26, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder Cannabis” or the “Company“) is excited to announce that, in celebration of Canada Day, it will launch its new Hemp Energy Drink line over the Canada Day long weekend, on June 29, across its existing Ontario locations, as well as its two brand new accessories stores in Niagara Falls and Pickering, set to open this weekend. Samples will be available at all locations.

As previously disclosed in the Company’s press release of June 18, 2019, Spyder Cannabis signed an exclusive agreement with Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF), to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores, vape stores, and kiosks in Canada and the United States.

“We are thrilled to launch a premium brand, the Hemp Energy Drink, to our customers this Canada Day long weekend, starting June 29th. This is a historic time for the Canadian hemp industry, and we are excited to be at the forefront of the retail and wholesale distribution of innovative new products. Our focus is on providing unique and distinctive quality hemp derived options, specially curated to meet the needs of all Canadians. We are looking forward to sharing our products throughout Canada,” stated Daniel Pelchovitz, CEO and President of Spyder.

About Spyder

Founded in 2014 Spyder is an established chain of three high-end vape stores in Ontario, with stores located in Woodbridge, Scarborough and Burlington. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and expanding into the legal cannabis and hemp derived market. Spyder has developed a scalable retail model with aggressive expansion plan to create a significant retail footprint with targeted and disciplined retail distribution strategy focusing on Canadian retail and U.S. hemp kiosks in high traffic peripheral areas.

About Tetra Natural Health:

Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For more information, visit: www.tetranaturalhealth.com.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Any number of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

]]>New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the UShttps://www.tetranaturalhealth.com/2019/06/new-hemp-energy-drink-to-be-offered-to-consumers-in-cannabis-accessory-stores-vapes-stores-and-kiosks-in-canada-and-the-us/
Tue, 18 Jun 2019 12:09:43 +0000https://tetranaturalhealth.com/?p=1171New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) – Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. […]

]]>New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US

OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) – Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyder”) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US. The drink is expected to be available to consumers in Spyder’s retail stores located in Scarborough, Woodbridge, Burlington, and shortly at the Niagara Falls and Pickering locations, which are expected to be opened early this summer. A launch event will be held during the Canada Day long weekend at the Niagara Falls location situated at 6474 Lundys Lane.

“We are very excited to be adding the Hemp Energy Drink to our portfolio of premium brands that will be available to our growing clientele,” stated Daniel Pelchovitz, CEO and President of Spyder. “This new offering will please our customers who are always seeking unique and distinctive quality products in this emerging industry.”

“This exclusive agreement allows us to take another step in implementing our distribution strategy and achieving our goal of making our Hemp Energy Drink accessible to all consumers “ said Richard Giguère, CEO of Tetra Natural Health “Consumers appreciate the qualities of the Hemp Energy Drink (HED) including the fact that it contains more natural ingredients than other energy drinks, and is the first energy drink made with hemp available in the country” adds Derek Theriault, National Sales Director of Tetra Natural Health.

About Tetra Natural Health:

Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For more information, visit: www.tetranaturalhealth.com

About Spyder Cannabis Inc.

Founded in 2014 Spyder is an established chain of three high-end vape stores in Ontario, with stores located in Woodbridge, Scarborough and Burlington. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis market. Spyder has developed a scalable retail model with an aggressive expansion plan to create a significant retail footprint with targeted and disciplined retail distribution strategy focusing on Canadian locations in high traffic peripheral areas.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Recently acquired by Tetra Bio-Pharma, Panag Pharma’s terpene-derived topical product is aimed at pain caused by osteoarthritis of the knee

OTTAWA, June 11, 2019 (GLOBE NEWSWIRE) — Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced completion of Panag 001, its Phase 3 clinical trial evaluating the safety and efficacy of Topical-A, now branded as Awaye for the treatment of pain caused by osteoarthritis of the knee. The last patient will be finished the open label phase this week and the last follow-up visits will be completed by the end of the third week of June. Panag will complete the analysis of the results and will communicate them to the market in the coming weeks. While the clinical study investigated the use of Awaye for osteoarthritis of the knee, it is currently approved by Health Canada for expanded indications including muscle and joint pain from arthritis.

About the Phase 3 Trial
The Phase 3 trial was a randomized, double-blind, placebo-controlled crossover trial with a 3-week open label extension. It was designed to demonstrate the safety and efficacy of its Awaye topical cream in participants with Osteoarthritis (OA) of the knee as per the criteria of the American College of rheumatology. The study design included 3 arms: placebo, Awaye and a third arm with a Beta-caryophyllene proprietary formulation. Patients received Awaye during the open label extension phase. Patients enrolled in the trial had osteoarthritis of the knee as per criteria established by the American College of Rheumatology. The Primary Endpoint of the study was the change in the mean daily pain diary score from baseline (average pain score over 7 days pre-treatment) to post treatment average for each treatment arm. Multiple Secondary Endpoints assessing pain, patient satisfaction and global impression of change were performed.

“This is the second study performed by Panag to demonstrate the safety and efficacy of Awaye in patients suffering from local pain,” says Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Panag has been working with Tetra’s commercialization team and expects to bring this product to consumers in the fourth quarter of 2019. We are also in discussions with potential commercialization partners from around the world. Awaye will be marketed by Tetra Natural Health, a subsidiary of Tetra Bio-Pharma.”

About Panag Pharma:

Panag Pharma Inc. is a Canadian-based life sciences company recently acquired by Tetra Bio-Pharma that is focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all, effective. The Panag Pharma team comprised of Ph.D. scientists and medical doctors are among the world’s leading researchers and clinicians in pain treatment and management. They bring a combined experience of over 100 years in research and the clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for application to the skin, the eyes as well as other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Awaye over the counter (OTC) cream provides a new approach to the treatment of chronic pain and inflammation.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Companybelieves, expects or anticipates will or may occur in the future (including, without limitation, statements regarding: the anticipated benefits of the Proposed Transaction for Tetra; completion and expected timing of the Proposed Transaction; whether the terms of the Proposed Transaction will be as described in this press release; whether the Proposed Transaction will be successful; the receipt of required regulatory approvals (including stock exchange) in respect of the Proposed Transaction)are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this topical product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. No definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

]]>OTTAWA, Ontario, May 14, 2019 (GLOBE NEWSWIRE) – Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce today that it has appointed Andre Rancourt, Greg Drohan, Guy Chamberland and Richard Giguère to its new board of directors, effective May 15, 2019. Mr. Rancourt will assume the role of Chairman of the Board of Directors. Tetra Natural Health (TNH) also announced the appointment of Chris MacLean as Chief Operating Officer.

“I am very pleased to welcome Greg Drohan, André Rancourt and Guy Chamberland as new directors to the Tetra Natural Health Board. Their extensive experience as senior executives in the consumer products market will bring tremendous vision and skills to the execution of the strategic moves and commercial expansion of Tetra Natural Health,” says Richard Giguere, Chief Executive Officer of Tetra Natural Health. “I am also thrilled to welcome Chris MacLean as COO of Tetra Natural Health to sustain and stimulate our company’s growth.”

Chris MacLean has more than ten years’ experience with small- to medium-sized start-ups. In addition to his responsibilities as COO of TNH, Chris will remain COO of Panag Pharma Inc., responsible for the company’s daily operations, securing funding and building important business relationships. In his previous roles, he helped develop Boondoc Technologies (The Rounds) and bring the company’s products to market. He played an integral part in the closing of Boondoc’s seed equity investment round, pitching the company to both angel investors and venture capital firms. Through his education and experience with new ventures, Chris has developed well-rounded knowledge in small business accounting, business development and company operations.

André Rancourt has extensive experience in the retail and professional natural health product market in Canada and the USA. For the last twenty years, he has acted as a senior executive or director in charge of marketing and driving sales of natural products across North America. His experience in negotiating contracts with distributors will be an asset, as it is a critical to the sales in this market. André Rancourt is highly experienced in management, start-ups and commercial strategies for human and agro products and acts as a consultant on many commercial strategy committees, including FIA and IRZC. He also has a considerable hands-on experience and expertise in many fields ranging from metals to the complex area of human and animal natural health products.

Greg Drohan will be Tetra Bio-Pharma’s representative on the TNH board. While at Church and Dwight Canada, Drohan successfully merged the Church & Dwight and Carter-Horner businesses, which doubled sales revenue and helped achieve a top market share for brands such as Trojan, OxiClean, First Response, Rub A535 and Arm & Hammer. Following his successful 40-year career in the consumer products sector, Mr. Drohan set up a management consulting practice. His previous board experiences include President on the Board of Church and Dwight and director of the Ryerson University Alumni Relations Board. Drohan holds an MBA from York University and a BBM from Ryerson Polytechnical Institute.

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, has unique expertise on the professional side of the NHP market, including the U.S. naturopathic market. His extensive and broad-based experience in both executive and scientific roles have established Dr. Chamberland as a seasoned and knowledgeable professional in the biopharmaceutical space. Dr. Chamberland has over 22 years’ experience in new drug development for the pharmaceutical industry (Canada and U.S.), with specific expertise in regulatory affairs and the development and management of clinical research protocols and clinical studies for botanical medicines. He also was a member of the investment committee of the venture capital fund Fonds Bionvation for seven years.

About Tetra Natural Health:

Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp-based natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information: www.tetranaturalhealth.com

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

OTTAWA, Ontario, April 30, 2019 (GLOBE NEWSWIRE) – Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made from hemp in the country. In the coming weeks, Tetra Natural Health will be in a position to supply the entire country from its distribution centres in Montreal (for the Quebec and Maritimes market), Toronto (for the Ontario and central Canada market) and Vancouver (for the Western Canada market).

Since the beginning of the year, Hemp Energy Drink (www.hempenergydrink.ca) has been available in many stores across Western Canada. Consumers have greatly appreciated this refreshing, low-calorie beverage with many natural ingredients that comes in three flavours: classic, mango and raspberry.

“We’re delighted that large quantities of Hemp Energy Drink have finally arrived and look forward to Canadian consumers getting a chance to have easy access to and taste this unique and refreshing beverage,” said Richard Giguère, CEO of Tetra Natural Health. “We thank Canadians for their patience, which will soon be rewarded since Hemp Energy Drink will be available in many stores across the country”.

About Tetra Natural Health

Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information: www.tetranaturalhealth.com

About Tetra Bio-Pharma

Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information, visitez: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

]]>The Hemp Energy Drink arrives in store!https://www.tetranaturalhealth.com/2019/02/the-hemp-energy-drink-arrives-in-store/
Mon, 18 Feb 2019 14:10:48 +0000https://tetranaturalhealth.com/?p=580Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma, announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan. The tastings of the Hemp Energy Drink were very popular on February 2 and 3, during the Wellness Show Vancouver 2019 and at a product presentation in Kelowna. The distribution plan is expected to accelerate the penetration of HED attractive green cans in stores in the coming weeks. [...]

In Alberta, the Hemp Energy Drink can be found in Athabasca, Banff, Boyle and Langdon, and in Saskatchewan in Kindersley and Tisdale. Visit www.hempenergydrink.ca to find the stores.

The tastings of the Hemp Energy Drink were very popular on February 2 and 3, during the Wellness Show Vancouver 2019 and at a product presentation in Kelowna. The distribution plan is expected to accelerate the penetration of HED attractive green cans in stores in the coming weeks.

“Our distribution plan is on schedule and the arrival of the Hemp Energy Drink is creating a buzz among consumers as soon as the product becomes available in store,” said Richard Giguère, Chief Executive Officer, Tetra Natural Health. “We will accelerate the deployment of our market opening strategy in a few weeks with the arrival of 1,700,000 cans of Hemp Energy Drink, of which more than 600,000 will be quickly shipped to new markets in Canada”.

Hemp Energy Drink is the first energy drink made from hemp in the country. Light, energizing, fresh, Hemp Energy Drink is licensed by Health Canada and contains fewer calories and more natural ingredients than any other energy drink. The product will soon be available in three flavors, classic, mango and raspberry, and it will be accessible in stores in a few months in all regions across Canada.

About Tetra Natural Health:

Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

]]>Tetra Natural Health Adds New Leaders to its Commercial Operationshttps://www.tetranaturalhealth.com/2019/01/tetra-natural-health-adds-new-leaders-to-its-commercial-operations/
Mon, 14 Jan 2019 17:08:57 +0000https://tetranaturalhealth.com/?p=467Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development, is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics. [...]

]]>ORLEANS, Ontario, Jan. 14, 2019 (GLOBE NEWSWIRE) — Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.

Derek Theriault, National Sales Director – has 20 years’ experience within the pharmaceutical industry and has held various sales and leadership roles during this time. He was pivotal to the launch of several companies including the development of their sales forces and penetration of the Canadian market. Derek has a proven track record for strategically building market-share for several brand name medications, over-the-counter (OTC) drugs and natural products. Derek is recognized for his ability to lead sales teams as well as to help grow the talent base within the organization while reaching and surpassing the milestones that were set forth. He is also known for his passion for coaching, his strong ethical standards and his ability to respond to seize opportunities.

Michael Olders, Director Operations and Logistics – With more than two decades of experience, Michael has held several leadership positions in Operations and Logistics in a variety of industries. Having worked for small privately-owned businesses as well as large multinational corporations, he is known for finding ways to increase efficiencies while lowering costs, often using technology to achieve significant positive results. Teamwork, communication and integrity are hallmarks of Michael’s approach to growing business and profits and exceeding goals. He studied at Selwyn House School, Collège Brébeuf and McGill University, and is passionate about continuous learning, technology, his family and the Montreal Canadiens.

“I am very proud to add Derek Theriault and Michael Olders to the Tetra Natural Health management team. Their combined solid experience and track records with OTC drugs and natural health products will enable us to grow our portfolio of products and our commercial results significantly over the coming year and contribute to the consolidated results of Tetra Bio-Pharma,” says Richard Giguere, Chief Executive Officer of Tetra Natural Health.

About Tetra Natural Health:

Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Two photos accompanying this announcement are available at:http://www.globenewswire.com/NewsRoom/AttachmentNg/7d0b2157-04d4-4cf9-9c4e-1321278ae8d5http://www.globenewswire.com/NewsRoom/AttachmentNg/6d9ea9f6-9ca3-4f8d-b8f1-ffbf17bff3d6